

A Multi-center, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Efficacy of Subcutaneous and Intravenous Isatuximab (SAR650984) in Combination With Pomalidomide and Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical summary

Eligible patients will be randomised to receive isatuximab intravenously or subcutaneously, in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory Multiple Myeloma. The primary objective of the trial will be to evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV). Study duration will be variable, depending on treatment and follow up periods, including 21 days of screening. Treatment will be administered until disease progression, unacceptable adverse reaction or other reason for discontinuation. End of treatment will be 30 days after last administration of isatuximab, or approximately 14 months after the first study treatment.

Conditions

This trial is treating patients with Multiple Myeloma

Trial Acronym

Cancer

Multiple Myeloma

Trial Identifiers

NCT04045795

TCD15484

Age: 18+

Phase: I

For full trial details, visit trials.cancervic.org.au/details/vctl_nct04045795